drugset / Trial / NCT05005728
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior therapy.
Timeline
- Start
- 2021-10-22
- Primary completion
- 2025-06-10
- Completion
- 2025-06-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabazitaxel | Other / unclassified | — | Intravenous |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Subject | Olaparib | Small molecule | — | Oral |
| Subject | Vudalimab | Monoclonal antibody | — | Intravenous |